Overview of oral cavity squamous cell carcinoma: Risk factors, mechanisms, and diagnostics.
Chamoli A, Gosavi AS, Shirwadkar UP, Wangdale KV, Behera SK, Kurrey NK, Kalia K, Mandoli A.
Oral Oncol. 2021 Oct;121:105451. doi: 10.1016/j.oraloncology.2021.105451. Epub 2021 Jul 28.
Head and neck squamous cell carcinoma.
Johnson DE, Burtness B, Leemans CR, Lui VWY, Bauman JE, Grandis JR.
Nat Rev Dis Primers. 2020 Nov 26;6(1):92. doi: 10.1038/s41572-020-00224-3.
Epidemiology, Risk Factors, and Prevention of Head and Neck Squamous Cell Carcinoma.
Barsouk A, Aluru JS, Rawla P, Saginala K, Barsouk A.
Med Sci (Basel). 2023 Jun 13;11(2):42. doi: 10.3390/medsci11020042.
The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC).
Cohen EEW, Bell RB, Bifulco CB, Burtness B, Gillison ML, Harrington KJ, Le QT, Lee NY, Leidner R, Lewis RL, Licitra L, Mehanna H, Mell LK, Raben A, Sikora AG, Uppaluri R, Whitworth F, Zandberg DP, Ferris RL.
J Immunother Cancer. 2019 Jul 15;7(1):184. doi: 10.1186/s40425-019-0662-5.
Target volume selection and delineation (T and N) for primary radiation treatment of oral cavity, oropharyngeal, hypopharyngeal and laryngeal squamous cell carcinoma.
Grégoire V, Grau C, Lapeyre M, Maingon P.
Oral Oncol. 2018 Dec;87:131-137. doi: 10.1016/j.oraloncology.2018.10.034. Epub 2018 Nov 3.
Head and neck squamous cell carcinoma: Genomics and emerging biomarkers for immunomodulatory cancer treatments.
Solomon B, Young RJ, Rischin D.
Semin Cancer Biol. 2018 Oct;52(Pt 2):228-240. doi: 10.1016/j.semcancer.2018.01.008. Epub 2018 Jan 31.
Xevinapant or placebo plus chemoradiotherapy in locally advanced squamous cell carcinoma of the head and neck: TrilynX phase III study design.
Bourhis J, Burtness B, Licitra LF, Nutting C, Schoenfeld JD, Omar M, Bouisset F, Nauwelaerts H, Urfer Y, Zanna C, Cohen EE.
Future Oncol. 2022 May;18(14):1669-1678. doi: 10.2217/fon-2021-1634. Epub 2022 Feb 17.
Non-Squamous Cell Malignancies of the Larynx.
Rotsides JM, Patel E, Oliver JR, Moses LE, Jacobson AS, Hu KS, Vaezi A, Tam M, Givi B.
Laryngoscope. 2022 Sep;132(9):1771-1777. doi: 10.1002/lary.30007. Epub 2022 Jan 7.
Avelumab plus standard-of-care chemoradiotherapy versus chemoradiotherapy alone in patients with locally advanced squamous cell carcinoma of the head and neck: a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial.
Lee NY, Ferris RL, Psyrri A, Haddad RI, Tahara M, Bourhis J, Harrington K, Chang PM, Lin JC, Razaq MA, Teixeira MM, Lövey J, Chamois J, Rueda A, Hu C, Dunn LA, Dvorkin MV, De Beukelaer S, Pavlov D, Thurm H, Cohen E.
Lancet Oncol. 2021 Apr;22(4):450-462. doi: 10.1016/S1470-2045(20)30737-3.
Pembrolizumab versus cetuximab concurrent with radiotherapy in patients with locally advanced squamous cell carcinoma of head and neck unfit for cisplatin (GORTEC 2015-01 PembroRad): a multicenter, randomized, phase II trial.
Tao Y, Biau J, Sun XS, Sire C, Martin L, Alfonsi M, Prevost JB, Modesto A, Lafond C, Tourani JM, Miroir J, Kaminsky MC, Coutte A, Liem X, Chautard E, Vauleon E, Drouet F, Ruffier A, Ramee JF, Waksi G, Péchery A, Wanneveich M, Guigay J, Aupérin A, Bourhis J.
Ann Oncol. 2023 Jan;34(1):101-110. doi: 10.1016/j.annonc.2022.10.006. Epub 2022 Oct 28.
